Amgen’s Sotorasib Updates Raise New Questions For KRAS Program
Lower Dose Being Tested Against Higher Dose Under FDA Review
The company provided updates on the timing of some data from its extensive clinical program for its KRAS G12C inhibitor Lumakras, but not for certain high-profile combinations.
